Consensus statement on peritoneal mesothelioma

Marcello Deraco, David Bartlett, Shigeki Kusamura, Dario Baratti

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) has been traditionally regarded as a rapidly lethal disease. Recently, several independent prospective trials have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with peri-operative intra-peritoneal chemotherapy (PIC). However, most of the surgical data comes from mono-institutional phase I or II studies and there is a broad range of variability regarding inclusion criteria, cytoreductive surgical procedures, drugs, temperatures and methods of delivering the heated chemotherapy (open vs. closed abdomen). This manuscript critically analyze and discuss the results of a group of health care providers trying to achieve a consensus statement in the management of this group of patients. The main conflicting points regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions. A questionnaire was placed on the website of the "5th International Workshop on Peritoneal Surface Malignancies" and the group members voted via internet. The results were presented for further debate during a dedicated session of the Workshop. The general treatment guidelines and future investigational perspectives were defined.

Original languageEnglish
Pages (from-to)268-272
Number of pages5
JournalJournal of Surgical Oncology
Volume98
Issue number4
DOIs
Publication statusPublished - Sep 15 2008

Fingerprint

Mesothelioma
Education
Drug Therapy
Health Personnel
Internet
Abdomen
Therapeutics
Guidelines
Temperature
Survival
Pharmaceutical Preparations
Neoplasms

Keywords

  • Consensus
  • Cytoreductive surgery
  • HIPEC
  • Hyperthermic intra-peritoneal chemotherapy
  • Peritoneal mesothelioma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Consensus statement on peritoneal mesothelioma. / Deraco, Marcello; Bartlett, David; Kusamura, Shigeki; Baratti, Dario.

In: Journal of Surgical Oncology, Vol. 98, No. 4, 15.09.2008, p. 268-272.

Research output: Contribution to journalArticle

Deraco, Marcello ; Bartlett, David ; Kusamura, Shigeki ; Baratti, Dario. / Consensus statement on peritoneal mesothelioma. In: Journal of Surgical Oncology. 2008 ; Vol. 98, No. 4. pp. 268-272.
@article{f6e77634d18d45aa8155fa8b527cbfde,
title = "Consensus statement on peritoneal mesothelioma",
abstract = "Diffuse malignant peritoneal mesothelioma (DMPM) has been traditionally regarded as a rapidly lethal disease. Recently, several independent prospective trials have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with peri-operative intra-peritoneal chemotherapy (PIC). However, most of the surgical data comes from mono-institutional phase I or II studies and there is a broad range of variability regarding inclusion criteria, cytoreductive surgical procedures, drugs, temperatures and methods of delivering the heated chemotherapy (open vs. closed abdomen). This manuscript critically analyze and discuss the results of a group of health care providers trying to achieve a consensus statement in the management of this group of patients. The main conflicting points regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions. A questionnaire was placed on the website of the {"}5th International Workshop on Peritoneal Surface Malignancies{"} and the group members voted via internet. The results were presented for further debate during a dedicated session of the Workshop. The general treatment guidelines and future investigational perspectives were defined.",
keywords = "Consensus, Cytoreductive surgery, HIPEC, Hyperthermic intra-peritoneal chemotherapy, Peritoneal mesothelioma",
author = "Marcello Deraco and David Bartlett and Shigeki Kusamura and Dario Baratti",
year = "2008",
month = "9",
day = "15",
doi = "10.1002/jso.21055",
language = "English",
volume = "98",
pages = "268--272",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Consensus statement on peritoneal mesothelioma

AU - Deraco, Marcello

AU - Bartlett, David

AU - Kusamura, Shigeki

AU - Baratti, Dario

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Diffuse malignant peritoneal mesothelioma (DMPM) has been traditionally regarded as a rapidly lethal disease. Recently, several independent prospective trials have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with peri-operative intra-peritoneal chemotherapy (PIC). However, most of the surgical data comes from mono-institutional phase I or II studies and there is a broad range of variability regarding inclusion criteria, cytoreductive surgical procedures, drugs, temperatures and methods of delivering the heated chemotherapy (open vs. closed abdomen). This manuscript critically analyze and discuss the results of a group of health care providers trying to achieve a consensus statement in the management of this group of patients. The main conflicting points regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions. A questionnaire was placed on the website of the "5th International Workshop on Peritoneal Surface Malignancies" and the group members voted via internet. The results were presented for further debate during a dedicated session of the Workshop. The general treatment guidelines and future investigational perspectives were defined.

AB - Diffuse malignant peritoneal mesothelioma (DMPM) has been traditionally regarded as a rapidly lethal disease. Recently, several independent prospective trials have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with peri-operative intra-peritoneal chemotherapy (PIC). However, most of the surgical data comes from mono-institutional phase I or II studies and there is a broad range of variability regarding inclusion criteria, cytoreductive surgical procedures, drugs, temperatures and methods of delivering the heated chemotherapy (open vs. closed abdomen). This manuscript critically analyze and discuss the results of a group of health care providers trying to achieve a consensus statement in the management of this group of patients. The main conflicting points regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions. A questionnaire was placed on the website of the "5th International Workshop on Peritoneal Surface Malignancies" and the group members voted via internet. The results were presented for further debate during a dedicated session of the Workshop. The general treatment guidelines and future investigational perspectives were defined.

KW - Consensus

KW - Cytoreductive surgery

KW - HIPEC

KW - Hyperthermic intra-peritoneal chemotherapy

KW - Peritoneal mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=50849108895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849108895&partnerID=8YFLogxK

U2 - 10.1002/jso.21055

DO - 10.1002/jso.21055

M3 - Article

C2 - 18726890

AN - SCOPUS:50849108895

VL - 98

SP - 268

EP - 272

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -